Pancreatic Cancer Research

ResearcherHirosaki UniversityActive in the last 2 years

Taiichi Wakiya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3681-7736; OpenAlex author ID A5005163574. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 10

  1. Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Prop… Co-author DOI 10.1016/j.jss.2026.08.063↗
  2. Noninvasive Computed Tomography-Based Deep Learning Model Predicts In Vitro Chemosensitivity Assay Results in Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002270↗
  3. Postoperative long‑term outcomes of acute normovolemic hemodilution in pancreatic cancer: A propensity score matching analysis. Co-author DOI 10.3892/ol.2024.14369↗
  4. ASO Author Reflections: Reconsidering the Treatment Strategy for Resectable Pancreatic Cancer Using a Biomarker-Based Scoring System for Prediction of Early Re… Co-author DOI 10.1245/s10434-021-10920-3↗
  5. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12379↗
  6. Roles of the nervous system in pancreatic cancer. Co-author DOI 10.1002/ags3.12459↗
  7. Eukaryotic initiation factor 2 signaling behind neural invasion linked with lymphatic and vascular invasion in pancreatic cancer. Co-author DOI 10.1038/s41598-021-00727-3↗
  8. Intraoperative Allogeneic Red Blood Cell Transfusion Negatively Influences Prognosis After Radical Surgery for Pancreatic Cancer: A Propensity Score Matching A… First author DOI 10.1097/mpa.0000000000001913↗
  9. Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer. Co-author DOI 10.3892/mco.2017.1251↗
  10. [Study of unresectable pancreatic cancer - successful resections after gemcitabine-based chemotherapy]. Co-author PMID 24393952↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichi Hakamada · 10 shared papers, 2013–2026 · strength 1.59
  2. Keinosuke Ishido · 10 shared papers, 2013–2026 · strength 1.59
  3. Hayato Nagase · 6 shared papers, 2021–2026 · strength 1.12
  4. Taishu Kanda · 6 shared papers, 2021–2024 · strength 0.98
  5. Yusuke Wakasa · 1 shared paper, 2026 · strength 0.32
  6. Satoru Tsuruta · 1 shared paper, 2026 · strength 0.32
  7. Tadashi Yoshizawa · 2 shared papers, 2021 · strength 0.29
  8. Eri Yoshida · 1 shared paper, 2024 · strength 0.20
  9. Yutaro Hara · 1 shared paper, 2022 · strength 0.16
  10. Hiroshi Kijima · 1 shared paper, 2021 · strength 0.12
  11. Daisuke Kudo · 2 shared papers, 2013–2017 · strength 0.12
  12. Takeshi Saito · 1 shared paper, 2017 · strength 0.08
  13. Shingo Sakuraba · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.